{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=0.9%25+Sodium+Chloride+Injection%2C+USP",
    "query": {
      "intervention": "0.9% Sodium Chloride Injection, USP"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 126,
    "total_pages": 13,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=0.9%25+Sodium+Chloride+Injection%2C+USP&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-28T13:38:08.543Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00454818",
      "title": "Efficacy and Safety Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Heart Failure, Congestive",
        "Dilated Cardiomyopathy"
      ],
      "interventions": [
        {
          "name": "MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study)",
          "type": "GENETIC"
        },
        {
          "name": "Placebo Infusion",
          "type": "PROCEDURE"
        },
        {
          "name": "MYDICAR Phase 2 (Placebo-controlled, Randomized Study)",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "PROCEDURE"
      ],
      "sponsor": "Celladon Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 51,
      "start_date": "2007-03",
      "completion_date": "2012-08",
      "has_results": true,
      "last_update_posted_date": "2014-08-20",
      "last_synced_at": "2026-09-28T13:38:08.543Z",
      "location_count": 22,
      "location_summary": "San Diego, California • Gainesville, Florida • Chicago, Illinois + 15 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00454818"
    },
    {
      "nct_id": "NCT00730964",
      "title": "A Prospective Surveillance Trial to Evaluate the Safety of Optison in Clinical Practice.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Echocardiography"
      ],
      "interventions": [
        {
          "name": "Perflutren Protein-Type A Microspheres Injectable Suspension, United States Pharmacopeia (USP)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GE Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1039,
      "start_date": "2008-05",
      "completion_date": "2009-10",
      "has_results": true,
      "last_update_posted_date": "2012-06-12",
      "last_synced_at": "2026-09-28T13:38:08.543Z",
      "location_count": 1,
      "location_summary": "Princeton, New Jersey",
      "locations": [
        {
          "city": "Princeton",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00730964"
    },
    {
      "nct_id": "NCT04492475",
      "title": "Adaptive COVID-19 Treatment Trial 3 (ACTT-3)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "Interferon beta-1a",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Remdesivir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 969,
      "start_date": "2020-08-05",
      "completion_date": "2020-12-21",
      "has_results": true,
      "last_update_posted_date": "2022-03-14",
      "last_synced_at": "2026-09-28T13:38:08.543Z",
      "location_count": 55,
      "location_summary": "Birmingham, Alabama • Fresno, California • La Jolla, California + 45 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04492475"
    },
    {
      "nct_id": "NCT04401527",
      "title": "Treatment of Lung Injury From COVID-19 Infection With Intravenous Sodium Nitrite",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID-19",
        "Acute Respiratory Distress Syndrome",
        "Acute Respiratory Failure"
      ],
      "interventions": [
        {
          "name": "Sodium Nitrite",
          "type": "DRUG"
        },
        {
          "name": "Normal Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hope Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2020-07-22",
      "completion_date": "2020-08-15",
      "has_results": false,
      "last_update_posted_date": "2020-09-16",
      "last_synced_at": "2026-09-28T13:38:08.543Z",
      "location_count": 2,
      "location_summary": "Tampa, Florida • Fort Worth, Texas",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04401527"
    },
    {
      "nct_id": "NCT06546709",
      "title": "DMID 23-0015; Lassa Fever CVD 1000",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lassa Fever"
      ],
      "interventions": [
        {
          "name": "LASSARAB+ aPHAD-SEat 700rU",
          "type": "BIOLOGICAL"
        },
        {
          "name": "HDCV Comparator",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Normal Saline Placebo",
          "type": "OTHER"
        },
        {
          "name": "LASSARAB+ aPHAD-SEat 1400rU",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Wilbur Chen, MD, MS",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 54,
      "start_date": "2025-01-13",
      "completion_date": "2026-05-11",
      "has_results": false,
      "last_update_posted_date": "2026-09-24",
      "last_synced_at": "2026-09-28T13:38:08.543Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06546709"
    },
    {
      "nct_id": "NCT01689363",
      "title": "Evaluation of the Allergenicity of AMPHADASE INJECTION (Hyaluronidase Injection USP)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Allergic Skin Reaction"
      ],
      "interventions": [
        {
          "name": "Hyaluronidase",
          "type": "DRUG"
        },
        {
          "name": "Histamine",
          "type": "DRUG"
        },
        {
          "name": "Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amphastar Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 253,
      "start_date": "2012-09",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2017-01-20",
      "last_synced_at": "2026-09-28T13:38:08.543Z",
      "location_count": 5,
      "location_summary": "Eugene, Oregon • Lake Oswego, Oregon • Portland, Oregon + 2 more",
      "locations": [
        {
          "city": "Eugene",
          "state": "Oregon"
        },
        {
          "city": "Lake Oswego",
          "state": "Oregon"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Renton",
          "state": "Washington"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01689363"
    },
    {
      "nct_id": "NCT02697136",
      "title": "CER-001 Therapy as a Novel Approach to Treat Genetic Orphan Diseases",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Familial Hypoalphalipoproteinemia"
      ],
      "interventions": [
        {
          "name": "CER-001",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cerenis Therapeutics, SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2015-12",
      "completion_date": "2018-12-21",
      "has_results": true,
      "last_update_posted_date": "2025-07-22",
      "last_synced_at": "2026-09-28T13:38:08.543Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02697136"
    },
    {
      "nct_id": "NCT06606561",
      "title": "NANOVAE to Treat Knee Osteoarthritis (KOA)",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Knee Osteoarthritis"
      ],
      "interventions": [
        {
          "name": "NANOVAE - Acellular Allogenic Human Amniotic Fluid (hAF)",
          "type": "DRUG"
        },
        {
          "name": "0.9% Sodium Chloride Injection, USP",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nova Vita Laboratory",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "21 Years to 75 Years"
      },
      "enrollment_count": 24,
      "start_date": "2026-10-01",
      "completion_date": "2027-10-01",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-09-28T13:38:08.543Z",
      "location_count": 1,
      "location_summary": "Chesterfield, Missouri",
      "locations": [
        {
          "city": "Chesterfield",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06606561"
    },
    {
      "nct_id": "NCT02716675",
      "title": "Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection Among Men and Transgender Persons Who Have Sex With Men",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "VRC01",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo for VRC01",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "MALE",
        "summary": "18 Years to 50 Years · Male only"
      },
      "enrollment_count": 2699,
      "start_date": "2016-04-06",
      "completion_date": "2020-12-01",
      "has_results": true,
      "last_update_posted_date": "2022-02-23",
      "last_synced_at": "2026-09-28T13:38:08.543Z",
      "location_count": 19,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • San Francisco, California + 13 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02716675"
    },
    {
      "nct_id": "NCT06669403",
      "title": "OPT101 in Patients With Community Acquired Pneumonia (CAP) With Sepsis",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Sepsis",
        "Community Acquired Pneumonia (CAP)"
      ],
      "interventions": [
        {
          "name": "OPT101",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Op-T LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2025-12",
      "completion_date": "2026-05",
      "has_results": false,
      "last_update_posted_date": "2025-09-15",
      "last_synced_at": "2026-09-28T13:38:08.543Z",
      "location_count": 1,
      "location_summary": "Denver, Colorado",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06669403"
    }
  ]
}